Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).
Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.
A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.
Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.
CH Amiens Hôpital Sud, Amiens, France
CHU Angers, Angers, France
CH Victor Dupouy, Argenteuil, France
Novartis Investigative Site, Tokyo, Japan
Skane University Hospital, Lund, Sweden
Newcastle Clinical Trials Unit, Newcastle upon Tyne, Tyne And Wear, United Kingdom
Peking University People's Hospital, Beijing, Beijing, China
The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
GSK Investigational Site, Overland Park, Kansas, United States
PPD, Austin, Texas, United States
Qilu Hospital, Shandong University, Jinan, Shandong, China
M D Anderson Cancer Center, Houston, Texas, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.